Auxilium Pharmaceuticals ( AUXL) operates as a specialty biopharmaceutical company. It has been given a buy rating by UBS Investment Research. Despite the new competition in the testosterone market, Testim is expected to continue growing due to its patent protection. Xiaflex is expected to pick up improved reimbursement by 2016 and is also patent protected. UBS is of the opinion that the assets of the company will be able to fit into a larger company in the consolidating sector. Shares of Auxilium are currently trading at $20 per share and are expected to reach a target price of $26, indicating a potential upside of 30%. George Soros initiated a brand new position in AUXL during the third quarter.